+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Huntington's Disease Therapeutics - Global Market Trajectory & Analytics

  • PDF Icon

    Report

  • April 2021
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1227787

Competition in the Global HD Therapeutics Market is Non-existent

Global Huntington's Disease Therapeutics Market to Reach $3.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Huntington's Disease Therapeutics estimated at US$402.2 Million in the year 2020, is projected to reach a revised size of US$3.1 Billion by 2027, growing at a CAGR of 33.7% over the period 2020-2027.



The U.S. Market is Estimated at $107.7 Million, While China is Forecast to Grow at 41.6% CAGR

The Huntington's Disease Therapeutics market in the U.S. is estimated at US$107.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$821 Million by the year 2027 trailing a CAGR of 41.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 26.9% and 30.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 28.9% CAGR.

Select Competitors (Total 25 Featured):
  • Alnylam Pharmaceuticals, Inc.
  • Evotec AG
  • GlaxoSmithKline PLC
  • Horizon Therapeutics plc
  • Ionis Pharmaceuticals, Inc.
  • Raptor Pharmaceutical Corporation
  • Sangamo Biosciences, Inc.
  • Suven Life Sciences Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Inc.
  • Wave Life Sciences Ltd.
Frequently Asked Questions about the Global Market for Huntington's Disease Therapeutics

What is the estimated value of the Global Market for Huntington's Disease Therapeutics?

The Global Market for Huntington's Disease Therapeutics was estimated to be valued at $402.2 Million in 2020.

What is the growth rate of the Global Market for Huntington's Disease Therapeutics?

The growth rate of the Global Market for Huntington's Disease Therapeutics is 33.9%, with an estimated value of $3100 Million by 2027.

What is the forecasted size of the Global Market for Huntington's Disease Therapeutics?

The Global Market for Huntington's Disease Therapeutics is estimated to be worth $3100 Million by 2027.

Who are the key companies in the Global Market for Huntington's Disease Therapeutics?

Key companies in the Global Market for Huntington's Disease Therapeutics include Alnylam Pharmaceuticals, Inc., Evotec AG, GlaxoSmithKline PLC, Horizon Therapeutics plc, Ionis Pharmaceuticals, Inc., Raptor Pharmaceutical Corporation, Sangamo Biosciences, Inc., Suven Life Sciences Ltd. and Vertex Pharmaceuticals Inc..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • TABLE 2: World Historic Review for Huntington's Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 3: World 15-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
  • III. MARKET ANALYSIS
  • UNITED STATES
  • TABLE 4: USA Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 5: USA Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • CANADA
  • TABLE 6: Canada Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 7: Canada Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • JAPAN
  • TABLE 8: Japan Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 9: Japan Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • CHINA
  • TABLE 10: China Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 11: China Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • EUROPE
  • TABLE 12: Europe Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • TABLE 13: Europe Historic Review for Huntington's Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 14: Europe 15-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
  • FRANCE
  • TABLE 15: France Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 16: France Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • GERMANY
  • TABLE 17: Germany Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 18: Germany Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • ITALY
  • TABLE 19: Italy Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 20: Italy Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • UNITED KINGDOM
  • TABLE 21: UK Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 22: UK Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • SPAIN
  • TABLE 23: Spain Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 24: Spain Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • RUSSIA
  • TABLE 25: Russia Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 26: Russia Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • REST OF EUROPE
  • TABLE 27: Rest of Europe Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 28: Rest of Europe Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • ASIA-PACIFIC
  • TABLE 29: Asia-Pacific Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • TABLE 30: Asia-Pacific Historic Review for Huntington's Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 31: Asia-Pacific 15-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
  • AUSTRALIA
  • TABLE 32: Australia Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 33: Australia Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • INDIA
  • TABLE 34: India Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 35: India Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • SOUTH KOREA
  • TABLE 36: South Korea Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 37: South Korea Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • REST OF ASIA-PACIFIC
  • TABLE 38: Rest of Asia-Pacific Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 39: Rest of Asia-Pacific Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • LATIN AMERICA
  • TABLE 40: Latin America Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • TABLE 41: Latin America Historic Review for Huntington's Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 42: Latin America 15-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
  • ARGENTINA
  • TABLE 43: Argentina Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 44: Argentina Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • BRAZIL
  • TABLE 45: Brazil Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 46: Brazil Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • MEXICO
  • TABLE 47: Mexico Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 48: Mexico Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • REST OF LATIN AMERICA
  • TABLE 49: Rest of Latin America Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 50: Rest of Latin America Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • MIDDLE EAST
  • TABLE 51: Middle East Current & Future Analysis for Huntington's Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • TABLE 52: Middle East Historic Review for Huntington's Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 53: Middle East 15-Year Perspective for Huntington's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
  • IRAN
  • TABLE 54: Iran Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 55: Iran Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • ISRAEL
  • TABLE 56: Israel Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 57: Israel Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • SAUDI ARABIA
  • TABLE 58: Saudi Arabia Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 59: Saudi Arabia Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • UNITED ARAB EMIRATES
  • TABLE 60: UAE Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 61: UAE Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • REST OF MIDDLE EAST
  • TABLE 62: Rest of Middle East Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 63: Rest of Middle East Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • AFRICA
  • TABLE 64: Africa Current & Future Analysis for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 65: Africa Historic Review for Huntington's Disease Therapeutics by Segment - Huntingtons Disease Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

IV. COMPETITION
  • Total Companies Profiled: 25

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Alnylam Pharmaceuticals, Inc.
  • Evotec AG
  • GlaxoSmithKline PLC
  • Horizon Therapeutics plc
  • Ionis Pharmaceuticals, Inc.
  • Raptor Pharmaceutical Corporation
  • Sangamo Biosciences, Inc.
  • Suven Life Sciences Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Inc.
  • Wave Life Sciences Ltd.